United States Daily Briefing

Moderna shares more than doubled and set an intraday record while Merck climbed more than 10% after their jointly developed melanoma mRNA vaccine posted strong clinical results. The development validates mRNA technology's expansion into personalized oncology — the same platform that underpinned COVID-19 vaccines now targets individual tumor mutations. Healthcare sector ETFs reflected the move with the sector up 3.5% on the session, the day's strongest performer by a wide margin.

Intel fell 4.0% and AMD dropped 3.7% as the high-yield environment continued to compress valuations on capital-intensive semiconductor names. The sector-level tech drawdown (-1.1%) reflects a dual pressure: higher discount rates on future earnings AND the diplomatic risk premium from US-Iran tensions that spiked Treasury yields on August 18. The divergence from healthcare and select growth names (CRM, TSLA) underscores the market's preference today for near-term-earnings plays over long-duration semiconductor stories.

Insider activity in the past 72 hours ran 47:1 sell-to-buy by dollar value — 29 sales totaling $228M against a single $4.87M purchase of LWAY by Divisadero Street Capital. The standout seller was Chevron CEO Michael Wirth, who filed to sell 306,789 shares worth $61.5M. When C-suite insiders of energy majors take profits at this size while the geopolitical risk premium should theoretically support oil prices, the read is that valuation, not just liquidity, is the motive. Watch for additional Form 4 filings this week.